On July 30, 2020 Trillium Therapeutics Inc. ("Trillium" or the "Company") (NASDAQ/TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, reported an update today on its ongoing phase 1b dose optimization study of TTI-621 in patients with relapsed and/or refractory cutaneous T-cell lymphoma (CTCL) (Press release, Trillium Therapeutics, JUL 30, 2020, View Source [SID1234562589]). TTI-621 is an innate immune checkpoint inhibitor targeting CD47, a "don’t eat me" signal that cancer cells use to evade destruction by the immune system.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are pleased to report that we have successfully completed the safety assessment part of the 1.4 mg/kg cohort, with no DLTs observed," said Jan Skvarka, President and Chief Executive Officer of Trillium. "After experiencing a temporary slow-down in patient enrollment due to Covid-19, we are now moving ahead with the 2.0 mg/kg dose level, and anticipate dosing the first patient in early August 2020."
TTI-621 Phase 1b Study Update
15 relapsed/refractory CTCL patients have been enrolled in the first 4 cohorts, and were treated with TTI-621 monotherapy at doses up to 1.4 mg/kg.
Dose limiting toxicity (DLT) evaluation of Cohort 4 (1.4 mg/kg dose level) has been successfully completed and dose escalation is now continuing at 2.0 mg/kg.
Data related to clinical activity, pharmacokinetics and pharmacodynamics are not yet available for the 1.4 mg/kg cohort.
Trillium intends to provide an update on its TTI-621 and TTI-622 studies at the American Society for Hematology Annual Meeting in December 2020.
About TTI-621
TTI-621 is a SIRPαFc decoy receptor consisting of the CD47-binding domain of human SIRPα linked to an IgG1 Fc region. It is designed to enhance phagocytosis and anti-tumor activity by preventing CD47 from delivering its inhibitory signal. Importantly, TTI-621 does not bind appreciably to human red blood cells, providing a key differentiation feature.